Soris personal page - To The Moon

Soris

Soris

No personal profile

15Follow

2Followers

0Topic

0Badge

2021-06-14

hibjjhjj

2021-06-05

ok

Sorry, the original content has been removed

2021-05-13

ahem

Roku Stock Is Still Priced Right After Post-Earnings Boost

2021-05-08

comment n like

Investors back off view that Fed could raise rates in late 2022

2021-05-03

good

Tencent-backed insurance platform Waterdrop targets US$360 million US listing

2021-05-02

like me

2021-05-02

good to read

3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners

2021-05-02

down

3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581745590028997","uuid":"3581745590028997","gmtCreate":1618839763726,"gmtModify":1619327224071,"name":"Soris","pinyin":"soris","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":15,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.99%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":184367130,"gmtCreate":1623685148320,"gmtModify":1704208733132,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"hibjjhjj","listText":"hibjjhjj","text":"hibjjhjj","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184367130","isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112596826,"gmtCreate":1622882603265,"gmtModify":1704192961532,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112596826","repostId":"1148130971","repostType":4,"isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191438381,"gmtCreate":1620897114443,"gmtModify":1704350074317,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"ahem","listText":"ahem","text":"ahem","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191438381","repostId":"1115369155","repostType":4,"repost":{"id":"1115369155","kind":"news","pubTimestamp":1620895435,"share":"https://ttm.financial/m/news/1115369155?lang=&edition=fundamental","pubTime":"2021-05-13 16:43","market":"us","language":"en","title":"Roku Stock Is Still Priced Right After Post-Earnings Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=1115369155","media":"InvestorPlace","summary":"After an extended slump, ROKU stock popped 11.6% on Friday after a big earnings win.\n\nRoku(NASDAQ:RO","content":"<blockquote>\n After an extended slump, ROKU stock popped 11.6% on Friday after a big earnings win.\n</blockquote>\n<p><b>Roku</b>(NASDAQ:<b><u>ROKU</u></b>) holds an interesting position in the video streaming war. The company is a long-time player — a streaming pioneer, really. Roku hardware and smart TVs running Roku software are in more American homes than any competing systems. Those Roku devices are typically used to access other streaming video services. However, Roku’s strategy of selling advertising on its free Roku Channel is increasingly paying off. In its latest quarter, the company beat analyst expectations and posted a surprise profit. The market responded with an 11.6% pop for ROKU stock.</p>\n<p>A month ago,I wrotethat the Roku Channel was likely to pay off for the company, making ROKU stock well worth considering. My timing was a little off. ROKU continued to slide. But the company’s first-quarter earnings win shows that the Roku Channel has been a smart move.</p>\n<p>I suspect the worst of the stock’s 2021 slump is now behind it. In which case, now would be the time to make a move if you want to add this video streaming pioneer to your portfolio.</p>\n<p><b>A Killer First Quarter Boosts ROKU Stock</b></p>\n<p>In February, Roku delivered its full-year 2020 numbers. They were very good. Revenue was up 58% year over year, the company added 14.3 million active accounts and platform revenue was up 71%. It’s no coincidence that in February, ROKU stock was trading at all-time highs.</p>\n<p>Analysts weren’t expecting the picture for the first quarter to be quite so strong. Wall Street was looking forQ1 revenue of $490.6 million, with a loss of 13 cents per share. The reasoning was that much of that 2020 performance was attributable to the coronavirus pandemic. People were staying at home and starved for entertainment. With vaccinations under way and the country opening up, being parked in front of a TV would be losing its appeal.</p>\n<p>Rokuproved the sceptics wrong. Revenue for the quarter grew 79% YoY, hitting $574.2 million. Platform revenue was up 101% YoY. The company added 2.4 million new active user accounts and the average revenue per user grew 32% YoY. Roku even beat its own projection for a loss on the quarter, instead delivering earnings per share of 59 cents.</p>\n<p>The company’s Roku Channel now reaches 70 million U.S. households. That growth has helped to drive advertising revenue for free content, and generated the cash needed to fund original content. This, in turn, helps generate more ad revenue, in what Roku describes as the “Roku Channel flywheel.”</p>\n<p>The big earnings beat sent ROKU stock to a $317 close, a single-day gain of 11.6%.</p>\n<p><b>There Are Risks</b></p>\n<p>While the news from Roku was mostly positive for investors, the company did warn it faces potential headwinds. Analysts were quick to note that the pace of adding new active user accounts had slowed. It was up nearly 35% YoY, but that is the slowest pace of new account acquisitions in several years.</p>\n<p>Among Roku’s identified areas of concern are the expected slowdown in growth of ad spending (especially compared to the second half of 2020 when advertisers began spending big after clamping down early in the pandemic). The company is anticipating supply chain issues to persist through 2021 — impacting margins for Roku streamers and potentially disrupting Roku-equipped TV sales. And while Roku expects the addition of active user accounts to be better than pre-pandemic levels, with a return to normalcy the huge YoY growth numbers posted in 2020 may not be attainable.</p>\n<p><b>Bottom Line on ROKU Stock</b></p>\n<p>Factor out the slump that ROKU stock has been in since mid-February, and the growth picture is impressive. In the order of 1,670% over the past 5 years. It’s hard to argue against that kind of return.</p>\n<p>On the other side of the coin, as a<i>Portfolio Grader</i>‘B’ rated stock, the picture isn’t all roses. Roku itself has identified a number of potential headwinds to be faced. However, the company still sees “significant long-term opportunity ahead” and I think that nicely sums up the case for ROKU stock.</p>\n<p>Significant long-term growth opportunity ahead.</p>\n<p><i>On the date of publication, Louis Navellier had a long position in ROKU. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article. InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roku Stock Is Still Priced Right After Post-Earnings Boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoku Stock Is Still Priced Right After Post-Earnings Boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 16:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/roku-stock-is-still-priced-right-after-post-earnings-boost/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After an extended slump, ROKU stock popped 11.6% on Friday after a big earnings win.\n\nRoku(NASDAQ:ROKU) holds an interesting position in the video streaming war. The company is a long-time player — a ...</p>\n\n<a href=\"https://investorplace.com/2021/05/roku-stock-is-still-priced-right-after-post-earnings-boost/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc"},"source_url":"https://investorplace.com/2021/05/roku-stock-is-still-priced-right-after-post-earnings-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115369155","content_text":"After an extended slump, ROKU stock popped 11.6% on Friday after a big earnings win.\n\nRoku(NASDAQ:ROKU) holds an interesting position in the video streaming war. The company is a long-time player — a streaming pioneer, really. Roku hardware and smart TVs running Roku software are in more American homes than any competing systems. Those Roku devices are typically used to access other streaming video services. However, Roku’s strategy of selling advertising on its free Roku Channel is increasingly paying off. In its latest quarter, the company beat analyst expectations and posted a surprise profit. The market responded with an 11.6% pop for ROKU stock.\nA month ago,I wrotethat the Roku Channel was likely to pay off for the company, making ROKU stock well worth considering. My timing was a little off. ROKU continued to slide. But the company’s first-quarter earnings win shows that the Roku Channel has been a smart move.\nI suspect the worst of the stock’s 2021 slump is now behind it. In which case, now would be the time to make a move if you want to add this video streaming pioneer to your portfolio.\nA Killer First Quarter Boosts ROKU Stock\nIn February, Roku delivered its full-year 2020 numbers. They were very good. Revenue was up 58% year over year, the company added 14.3 million active accounts and platform revenue was up 71%. It’s no coincidence that in February, ROKU stock was trading at all-time highs.\nAnalysts weren’t expecting the picture for the first quarter to be quite so strong. Wall Street was looking forQ1 revenue of $490.6 million, with a loss of 13 cents per share. The reasoning was that much of that 2020 performance was attributable to the coronavirus pandemic. People were staying at home and starved for entertainment. With vaccinations under way and the country opening up, being parked in front of a TV would be losing its appeal.\nRokuproved the sceptics wrong. Revenue for the quarter grew 79% YoY, hitting $574.2 million. Platform revenue was up 101% YoY. The company added 2.4 million new active user accounts and the average revenue per user grew 32% YoY. Roku even beat its own projection for a loss on the quarter, instead delivering earnings per share of 59 cents.\nThe company’s Roku Channel now reaches 70 million U.S. households. That growth has helped to drive advertising revenue for free content, and generated the cash needed to fund original content. This, in turn, helps generate more ad revenue, in what Roku describes as the “Roku Channel flywheel.”\nThe big earnings beat sent ROKU stock to a $317 close, a single-day gain of 11.6%.\nThere Are Risks\nWhile the news from Roku was mostly positive for investors, the company did warn it faces potential headwinds. Analysts were quick to note that the pace of adding new active user accounts had slowed. It was up nearly 35% YoY, but that is the slowest pace of new account acquisitions in several years.\nAmong Roku’s identified areas of concern are the expected slowdown in growth of ad spending (especially compared to the second half of 2020 when advertisers began spending big after clamping down early in the pandemic). The company is anticipating supply chain issues to persist through 2021 — impacting margins for Roku streamers and potentially disrupting Roku-equipped TV sales. And while Roku expects the addition of active user accounts to be better than pre-pandemic levels, with a return to normalcy the huge YoY growth numbers posted in 2020 may not be attainable.\nBottom Line on ROKU Stock\nFactor out the slump that ROKU stock has been in since mid-February, and the growth picture is impressive. In the order of 1,670% over the past 5 years. It’s hard to argue against that kind of return.\nOn the other side of the coin, as aPortfolio Grader‘B’ rated stock, the picture isn’t all roses. Roku itself has identified a number of potential headwinds to be faced. However, the company still sees “significant long-term opportunity ahead” and I think that nicely sums up the case for ROKU stock.\nSignificant long-term growth opportunity ahead.\nOn the date of publication, Louis Navellier had a long position in ROKU. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article. InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":107388310,"gmtCreate":1620444940730,"gmtModify":1704343840051,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"comment n like","listText":"comment n like","text":"comment n like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/107388310","repostId":"1143709254","repostType":4,"repost":{"id":"1143709254","kind":"news","pubTimestamp":1620441083,"share":"https://ttm.financial/m/news/1143709254?lang=&edition=fundamental","pubTime":"2021-05-08 10:31","market":"us","language":"en","title":"Investors back off view that Fed could raise rates in late 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1143709254","media":"Reuters","summary":"(Reuters) -U.S. investors who had been betting the Fed would raise rates as early as the end of next","content":"<p>(Reuters) -U.S. investors who had been betting the Fed would raise rates as early as the end of next year abruptly retreated from those positions on Friday after a disappointing April employment report and now see the earliest the Fed might tighten roughly two years away.</p><p>The push back in expectations for when the Fed might start raising rates also means any reduction in the pace of its bond buying - which the Fed has said will begin first - may also occur later than some investors had been betting.</p><p>April’s employment growth came in far short of expectations, probably restrained by a shortage of workers and raw materials even as demand improved rapidly. It would be hard to argue it stands as “substantial further progress” toward maximum employment, the test the Fed has said it must achieve before it begins dialing back its massive support for the economy.</p><p>“It was a rude awakening. It could be what the Fed is worried about, that we’re going to continue to see uneven numbers and it’s not just going to be smooth sailing,” said George Goncalves, head of U.S. macro strategy at MUFG.</p><p>Following April’s meeting, investors were betting the Fed would raise rates in late 2022 or early 2023 and would offer clues about tapering its $120 million in monthly asset purchases as soon as June 2021.</p><p>U.S. interest rate futures on Friday, however, showed that traders pushed out expectations of a rate hike by roughly three months after Friday morning’s payrolls report. Eurodollar futures, a proxy for interest rate expectations, showed a 90% chance of an interest rate hike in March 2023, and fully priced in a hike in June 2023. Prior to the report, investors were betting there was a 90% chance of a hike in December 2022, and a 100% chance in March 2023.</p><p>Goncalves said that “we would probably need two to three more months like this to push back tapering.”</p><p>Investors still see the Fed needing to lay out a roadmap to tapering. Rick Rieder, BlackRock’s chief investment officer of global fixed income, said in a note that conditions “argue for at least beginning to lay out a plan for asset purchase tapering, even if the Fed is more likely to hold off on this transition for now.”</p><p>The change in interest rate expectations brings the market more in line with the Fed’s dovish approach to the coronavirus pandemic recovery. Though economic data has been improving, the Fed has said it has no plans to raise rates until maximum employment is achieved.</p><p>“I don’t believe this report changes the calculus of Powell or the core FOMC,” said Gregory Whiteley, portfolio manager at DoubleLine Capital.</p><p>“The Fed is looking for maximum employment. They’ve said it will take quite a while to get there. Today reinforces that idea - although a lack of strong GDP growth does not appear to be behind today’s disappointment.”</p><p>TD Securities strategist Penglu Zhao wrote in a note on Friday that speculators had last week piled into bearish bets on Treasury prices, on the expectation of a stellar payrolls print.</p><p>Commodity Futures Trading Commission data released on Friday showed that speculative positioning in U.S. 10-year Treasury futures flipped from a net long of 55,759 contracts to a net short of minus 7,245 contracts in the week through May 4.</p><p>Shorter-dated Treasury yields, which move with expectations of interest rates, fell in the wake of the report. The two-year yield, dropped to its lowest level since March, before recovering somewhat, last down 1 basis points to 0.147%.</p><p>Yields at the long end of the Treasury curve initially fell following the report, but quickly recovered. The 10-year yield, after hitting the lowest level since March 4, retraced the move to last trade at 1.579%, flat on the day.</p><p>Goncalves argued that the recovery in longer-dated yields was in anticipation of auctions of new 10- and 30-year bonds next week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors back off view that Fed could raise rates in late 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors back off view that Fed could raise rates in late 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-08 10:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-fed-rate-bets/update-2-investors-back-off-view-that-fed-could-raise-rates-in-late-2022-idUSL1N2MU16D><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -U.S. investors who had been betting the Fed would raise rates as early as the end of next year abruptly retreated from those positions on Friday after a disappointing April employment ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-fed-rate-bets/update-2-investors-back-off-view-that-fed-could-raise-rates-in-late-2022-idUSL1N2MU16D\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/usa-fed-rate-bets/update-2-investors-back-off-view-that-fed-could-raise-rates-in-late-2022-idUSL1N2MU16D","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143709254","content_text":"(Reuters) -U.S. investors who had been betting the Fed would raise rates as early as the end of next year abruptly retreated from those positions on Friday after a disappointing April employment report and now see the earliest the Fed might tighten roughly two years away.The push back in expectations for when the Fed might start raising rates also means any reduction in the pace of its bond buying - which the Fed has said will begin first - may also occur later than some investors had been betting.April’s employment growth came in far short of expectations, probably restrained by a shortage of workers and raw materials even as demand improved rapidly. It would be hard to argue it stands as “substantial further progress” toward maximum employment, the test the Fed has said it must achieve before it begins dialing back its massive support for the economy.“It was a rude awakening. It could be what the Fed is worried about, that we’re going to continue to see uneven numbers and it’s not just going to be smooth sailing,” said George Goncalves, head of U.S. macro strategy at MUFG.Following April’s meeting, investors were betting the Fed would raise rates in late 2022 or early 2023 and would offer clues about tapering its $120 million in monthly asset purchases as soon as June 2021.U.S. interest rate futures on Friday, however, showed that traders pushed out expectations of a rate hike by roughly three months after Friday morning’s payrolls report. Eurodollar futures, a proxy for interest rate expectations, showed a 90% chance of an interest rate hike in March 2023, and fully priced in a hike in June 2023. Prior to the report, investors were betting there was a 90% chance of a hike in December 2022, and a 100% chance in March 2023.Goncalves said that “we would probably need two to three more months like this to push back tapering.”Investors still see the Fed needing to lay out a roadmap to tapering. Rick Rieder, BlackRock’s chief investment officer of global fixed income, said in a note that conditions “argue for at least beginning to lay out a plan for asset purchase tapering, even if the Fed is more likely to hold off on this transition for now.”The change in interest rate expectations brings the market more in line with the Fed’s dovish approach to the coronavirus pandemic recovery. Though economic data has been improving, the Fed has said it has no plans to raise rates until maximum employment is achieved.“I don’t believe this report changes the calculus of Powell or the core FOMC,” said Gregory Whiteley, portfolio manager at DoubleLine Capital.“The Fed is looking for maximum employment. They’ve said it will take quite a while to get there. Today reinforces that idea - although a lack of strong GDP growth does not appear to be behind today’s disappointment.”TD Securities strategist Penglu Zhao wrote in a note on Friday that speculators had last week piled into bearish bets on Treasury prices, on the expectation of a stellar payrolls print.Commodity Futures Trading Commission data released on Friday showed that speculative positioning in U.S. 10-year Treasury futures flipped from a net long of 55,759 contracts to a net short of minus 7,245 contracts in the week through May 4.Shorter-dated Treasury yields, which move with expectations of interest rates, fell in the wake of the report. The two-year yield, dropped to its lowest level since March, before recovering somewhat, last down 1 basis points to 0.147%.Yields at the long end of the Treasury curve initially fell following the report, but quickly recovered. The 10-year yield, after hitting the lowest level since March 4, retraced the move to last trade at 1.579%, flat on the day.Goncalves argued that the recovery in longer-dated yields was in anticipation of auctions of new 10- and 30-year bonds next week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108578614,"gmtCreate":1620046111438,"gmtModify":1704337803957,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108578614","repostId":"1134322235","repostType":4,"repost":{"id":"1134322235","kind":"news","pubTimestamp":1620043120,"share":"https://ttm.financial/m/news/1134322235?lang=&edition=fundamental","pubTime":"2021-05-03 19:58","market":"us","language":"en","title":"Tencent-backed insurance platform Waterdrop targets US$360 million US listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1134322235","media":"South China Morning Post","summary":"Waterdrop, the online insurance and medical crowdfunding platform backed by Tencent, has started mar","content":"<p>Waterdrop, the online insurance and medical crowdfunding platform backed by Tencent, has started marketing its initial public offering (IPO) of up to US$360 million on the New York Stock Exchange.</p>\n<p>The Beijing-based firm is selling 30 million American depositary shares (ADS) in a range of US$10 to US$12 each, according to a term sheet seen by the<i>Post</i>. Each ADS represents 10 ordinary shares.</p>\n<p>Waterdrop has an option to sell up to 4.5 million more shares if there is strong demand. Joint book-runners on the deal include Goldman Sachs, Morgan Stanley and Bank of America.</p>\n<p>Do you have questions about the biggest topics and trends from around the world? Get the answers withSCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.</p>\n<p>Founded in 2016 by 33-year old Shen Peng, a former executive at China's food-delivery to ticket- booking platform Meituan, Waterdrop representsone of the latest Chinesefirms to list offshore.</p>\n<p>Waterdrop has secured indications of interest from both existing and new investors, which together seek to buy at least US$210 million worth of ADS, or about 63.6 per cent of the global offering. They include affiliates of Chinese private equity firms Boyu Capital and Hopu Investments. Tencent owns about 22.1 per cent of the firm and will be diluted during the listing.</p>\n<p><img src=\"https://static.tigerbbs.com/118527f3ed6ddb57fe1c79b1e34f3d27\" tg-width=\"704\" tg-height=\"388\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Shen Peng, founder of online insurance and medical crowdfunding platform Waterdrop. Source: Weibo alt=Shen Peng, founder of online insurance and medical crowdfunding platform Waterdrop. Source: Weibo</i></p>\n<p>Waterdrop claims to be the largest independent third-party life and health insurance distribution platform in China, having served some 79.4 million consumers as of the end of last year, according to itsUS filing.</p>\n<p>The loss-making company, which has 19.2 million paying customers, said it works with 62 insurance firms and offers 200 products on its platform. It primarily generates brokerage income from selling insurance policies underwritten by the insurers.</p>\n<p>Over the past three years, its net losses widened to 663.9 million yuan (US$102.5 million) in 2020 from 209.2 million in 2018. Apart from an insurance marketplace, it also runs a crowdfunding platform, through which it acquires users and converts them into paying customers. It claims its crowdfunding platform supported some 1.7 million patients who raised about 37 billion yuan from donors as of the end of last year.</p>\n<p>In China, the health care expenditure gap that is not covered by social or commercial medical insurance was estimated at 4.7 trillion yuan in 2019, underlying significant unmet medical protection demand in China, according to iResearch.</p>\n<p>Total premiums of the Chinese life and health insurance market will climb to 6.1 trillion yuan by 2024, soaring from 3.3 trillion yuan in 2020. Third-party insurance brokers and agents will likely account for 13 per cent of the market by 2024, up from just 3 per cent in 2020, according to iResearch.</p>\n<p>Waterdrop plans to use the net proceeds from its IPO on expanding its operations as well as on research and development.</p>\n<p>This article originally appeared in theSouth China Morning Post (SCMP), the most authoritative voice reporting on China and Asia for more than a century. For more SCMP stories, please explore theSCMP appor visit the SCMP'sFacebookandTwitterpages. Copyright © 2021 South China Morning Post Publishers Ltd. All rights reserved.</p>\n<p>Copyright (c) 2021. South China Morning Post Publishers Ltd. All rights reserved.</p>","source":"lsy1600132093512","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent-backed insurance platform Waterdrop targets US$360 million US listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent-backed insurance platform Waterdrop targets US$360 million US listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 19:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tencent-backed-insurance-platform-waterdrop-093000752.html><strong>South China Morning Post</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Waterdrop, the online insurance and medical crowdfunding platform backed by Tencent, has started marketing its initial public offering (IPO) of up to US$360 million on the New York Stock Exchange.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/tencent-backed-insurance-platform-waterdrop-093000752.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TCEHY":"腾讯控股ADR","00700":"腾讯控股","WDH":"水滴"},"source_url":"https://finance.yahoo.com/news/tencent-backed-insurance-platform-waterdrop-093000752.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134322235","content_text":"Waterdrop, the online insurance and medical crowdfunding platform backed by Tencent, has started marketing its initial public offering (IPO) of up to US$360 million on the New York Stock Exchange.\nThe Beijing-based firm is selling 30 million American depositary shares (ADS) in a range of US$10 to US$12 each, according to a term sheet seen by thePost. Each ADS represents 10 ordinary shares.\nWaterdrop has an option to sell up to 4.5 million more shares if there is strong demand. Joint book-runners on the deal include Goldman Sachs, Morgan Stanley and Bank of America.\nDo you have questions about the biggest topics and trends from around the world? Get the answers withSCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.\nFounded in 2016 by 33-year old Shen Peng, a former executive at China's food-delivery to ticket- booking platform Meituan, Waterdrop representsone of the latest Chinesefirms to list offshore.\nWaterdrop has secured indications of interest from both existing and new investors, which together seek to buy at least US$210 million worth of ADS, or about 63.6 per cent of the global offering. They include affiliates of Chinese private equity firms Boyu Capital and Hopu Investments. Tencent owns about 22.1 per cent of the firm and will be diluted during the listing.\n\nShen Peng, founder of online insurance and medical crowdfunding platform Waterdrop. Source: Weibo alt=Shen Peng, founder of online insurance and medical crowdfunding platform Waterdrop. Source: Weibo\nWaterdrop claims to be the largest independent third-party life and health insurance distribution platform in China, having served some 79.4 million consumers as of the end of last year, according to itsUS filing.\nThe loss-making company, which has 19.2 million paying customers, said it works with 62 insurance firms and offers 200 products on its platform. It primarily generates brokerage income from selling insurance policies underwritten by the insurers.\nOver the past three years, its net losses widened to 663.9 million yuan (US$102.5 million) in 2020 from 209.2 million in 2018. Apart from an insurance marketplace, it also runs a crowdfunding platform, through which it acquires users and converts them into paying customers. It claims its crowdfunding platform supported some 1.7 million patients who raised about 37 billion yuan from donors as of the end of last year.\nIn China, the health care expenditure gap that is not covered by social or commercial medical insurance was estimated at 4.7 trillion yuan in 2019, underlying significant unmet medical protection demand in China, according to iResearch.\nTotal premiums of the Chinese life and health insurance market will climb to 6.1 trillion yuan by 2024, soaring from 3.3 trillion yuan in 2020. Third-party insurance brokers and agents will likely account for 13 per cent of the market by 2024, up from just 3 per cent in 2020, according to iResearch.\nWaterdrop plans to use the net proceeds from its IPO on expanding its operations as well as on research and development.\nThis article originally appeared in theSouth China Morning Post (SCMP), the most authoritative voice reporting on China and Asia for more than a century. For more SCMP stories, please explore theSCMP appor visit the SCMP'sFacebookandTwitterpages. Copyright © 2021 South China Morning Post Publishers Ltd. All rights reserved.\nCopyright (c) 2021. South China Morning Post Publishers Ltd. All rights reserved.","news_type":1},"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101708843,"gmtCreate":1619938443982,"gmtModify":1704336606575,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"like me","listText":"like me","text":"like me","images":[{"img":"https://static.tigerbbs.com/2ea63e3418352fd346eb3cde1eaa52b1","width":"750","height":"1260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101708843","isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":101701391,"gmtCreate":1619938273513,"gmtModify":1704336604441,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"good to read","listText":"good to read","text":"good to read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101701391","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://ttm.financial/m/news/1115363330?lang=&edition=fundamental","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101703845,"gmtCreate":1619938232987,"gmtModify":1704336602972,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"down","listText":"down","text":"down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/101703845","repostId":"1165708828","repostType":4,"repost":{"id":"1165708828","kind":"news","pubTimestamp":1619792862,"share":"https://ttm.financial/m/news/1165708828?lang=&edition=fundamental","pubTime":"2021-04-30 22:27","market":"us","language":"en","title":"3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1165708828","media":"Motley Fool","summary":"For more than a year, patient investors have been handsomely rewarded. All three of the market's maj","content":"<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.</p>\n<p>Yet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in the<b>S&amp;P 500</b>,<b>Dow Jones Industrial Average</b>, and<b>Nasdaq Composite</b>, this represents a huge underperformance.</p>\n<p>But according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.</p>\n<p>Sarepta Therapeutics: Implied upside of 91%</p>\n<p>Many of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developer<b>Sarepta Therapeutics</b>(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.</p>\n<p>Sarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.</p>\n<p>However, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.&nbsp; In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.</p>\n<p>The Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.</p>\n<p>Intercept Pharmaceuticals: Implied upside of 97%</p>\n<p>If you wanteven more upside potential, Wall Street would steer you toward small-cap<b>Intercept Pharmaceuticals</b>(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.</p>\n<p>Similar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.</p>\n<p>Intercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.</p>\n<p>On the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.</p>\n<p>If OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.</p>\n<p>It's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.</p>\n<p>Inovio Pharmaceuticals: Implied upside of 104%</p>\n<p>Yet another biotech stock withbig-time upside potential, according to Wall Street, is<b>Inovio Pharmaceuticals</b>(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.</p>\n<p>For much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.</p>\n<p>Unfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.</p>\n<p>There are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players like<b>Johnson &amp; Johnson</b>&nbsp;can produce up to 3 billion doses for the global market this year. As a reminder, J&amp;J's vaccine is a single-dose treatment.</p>\n<p>The other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.</p>\n<p>With a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165708828","content_text":"For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.\nYet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in theS&P 500,Dow Jones Industrial Average, andNasdaq Composite, this represents a huge underperformance.\nBut according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.\nSarepta Therapeutics: Implied upside of 91%\nMany of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developerSarepta Therapeutics(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.\nSarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.\nHowever, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.  In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.\nThe Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.\nIntercept Pharmaceuticals: Implied upside of 97%\nIf you wanteven more upside potential, Wall Street would steer you toward small-capIntercept Pharmaceuticals(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.\nSimilar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.\nIntercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.\nOn the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.\nIf OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.\nIt's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.\nInovio Pharmaceuticals: Implied upside of 104%\nYet another biotech stock withbig-time upside potential, according to Wall Street, isInovio Pharmaceuticals(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.\nFor much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.\nUnfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.\nThere are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players likeJohnson & Johnson can produce up to 3 billion doses for the global market this year. As a reminder, J&J's vaccine is a single-dose treatment.\nThe other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.\nWith a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.","news_type":1},"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":101703845,"gmtCreate":1619938232987,"gmtModify":1704336602972,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"down","listText":"down","text":"down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/101703845","repostId":"1165708828","repostType":4,"repost":{"id":"1165708828","kind":"news","pubTimestamp":1619792862,"share":"https://ttm.financial/m/news/1165708828?lang=&edition=fundamental","pubTime":"2021-04-30 22:27","market":"us","language":"en","title":"3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1165708828","media":"Motley Fool","summary":"For more than a year, patient investors have been handsomely rewarded. All three of the market's maj","content":"<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.</p>\n<p>Yet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in the<b>S&amp;P 500</b>,<b>Dow Jones Industrial Average</b>, and<b>Nasdaq Composite</b>, this represents a huge underperformance.</p>\n<p>But according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.</p>\n<p>Sarepta Therapeutics: Implied upside of 91%</p>\n<p>Many of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developer<b>Sarepta Therapeutics</b>(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.</p>\n<p>Sarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.</p>\n<p>However, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.&nbsp; In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.</p>\n<p>The Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.</p>\n<p>Intercept Pharmaceuticals: Implied upside of 97%</p>\n<p>If you wanteven more upside potential, Wall Street would steer you toward small-cap<b>Intercept Pharmaceuticals</b>(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.</p>\n<p>Similar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.</p>\n<p>Intercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.</p>\n<p>On the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.</p>\n<p>If OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.</p>\n<p>It's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.</p>\n<p>Inovio Pharmaceuticals: Implied upside of 104%</p>\n<p>Yet another biotech stock withbig-time upside potential, according to Wall Street, is<b>Inovio Pharmaceuticals</b>(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.</p>\n<p>For much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.</p>\n<p>Unfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.</p>\n<p>There are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players like<b>Johnson &amp; Johnson</b>&nbsp;can produce up to 3 billion doses for the global market this year. As a reminder, J&amp;J's vaccine is a single-dose treatment.</p>\n<p>The other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.</p>\n<p>With a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165708828","content_text":"For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.\nYet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in theS&P 500,Dow Jones Industrial Average, andNasdaq Composite, this represents a huge underperformance.\nBut according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.\nSarepta Therapeutics: Implied upside of 91%\nMany of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developerSarepta Therapeutics(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.\nSarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.\nHowever, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.  In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.\nThe Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.\nIntercept Pharmaceuticals: Implied upside of 97%\nIf you wanteven more upside potential, Wall Street would steer you toward small-capIntercept Pharmaceuticals(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.\nSimilar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.\nIntercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.\nOn the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.\nIf OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.\nIt's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.\nInovio Pharmaceuticals: Implied upside of 104%\nYet another biotech stock withbig-time upside potential, according to Wall Street, isInovio Pharmaceuticals(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.\nFor much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.\nUnfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.\nThere are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players likeJohnson & Johnson can produce up to 3 billion doses for the global market this year. As a reminder, J&J's vaccine is a single-dose treatment.\nThe other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.\nWith a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.","news_type":1},"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":107388310,"gmtCreate":1620444940730,"gmtModify":1704343840051,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"comment n like","listText":"comment n like","text":"comment n like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/107388310","repostId":"1143709254","repostType":4,"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":191438381,"gmtCreate":1620897114443,"gmtModify":1704350074317,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"ahem","listText":"ahem","text":"ahem","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191438381","repostId":"1115369155","repostType":4,"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108578614,"gmtCreate":1620046111438,"gmtModify":1704337803957,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108578614","repostId":"1134322235","repostType":4,"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101701391,"gmtCreate":1619938273513,"gmtModify":1704336604441,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"good to read","listText":"good to read","text":"good to read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101701391","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://ttm.financial/m/news/1115363330?lang=&edition=fundamental","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112596826,"gmtCreate":1622882603265,"gmtModify":1704192961532,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112596826","repostId":"1148130971","repostType":4,"repost":{"id":"1148130971","kind":"news","pubTimestamp":1622866524,"share":"https://ttm.financial/m/news/1148130971?lang=&edition=fundamental","pubTime":"2021-06-05 12:15","market":"us","language":"en","title":"Can NIO Stock Reach $100? We Think It's A Matter Of 'When' Not 'If'","url":"https://stock-news.laohu8.com/highlight/detail?id=1148130971","media":"seekingalpha","summary":"NIO's share price has soared by more than 816% in the past year, peaking at almost $62 in early February before the growth stock sell-off in early March.We believe NIO's share price will soar beyond $160 by 2025 as global EV sales continue to ramp up with autonomous driving becoming a reality.NIO has continuously exhibited characteristics of an unsettling innovator. The brand is widely known for their breakthrough in battery swapping technology, “Power Swap”, which provides NIO owners with a fas","content":"<p><b>Summary</b></p>\n<ul>\n <li>NIO's share price has soared by more than 816% in the past year, peaking at almost $62 in early February before the growth stock sell-off in early March.</li>\n <li>The company's innovative approach and overseas expansion strategy, combined with the growing market sentiment on global electrification and automation are expected to boost the company's valuation.</li>\n <li>We believe NIO's share price will soar beyond $160 by 2025 as global EV sales continue to ramp up with autonomous driving becoming a reality.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7b31b2f189fa181e941126674e0b4c0b\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Drew Angerer/Getty Images News via Getty Images</span></p>\n<p>Despite it being a local Chinese electric vehicle (“EV”) brand that has only recently started its overseas expansion into Europe, NIO(NYSE:NIO)has already garnered significant international attention amidst avid investors within the EV sector in recent years. It has only been three short years since NIO made its first deliveries in mid-2018, yet many are already wondering whether its share price can reach similar heights as an industry leader, Tesla’s(NASDAQ:TSLA). Albeit a little farfetched given Tesla is currently trading at more than $600 per share with a market cap of more than $600 billion, we do believe NIO has promising potential to break $100 per share before 2025. Even Wall Street Analysts remain optimistic about the company’s future by assigning a&nbsp;price target of close to $60, which represents upward potential of more than 35% based on the last traded share price of $42.34 (June 1st).</p>\n<p>Founded in 2014, NIO has sold and delivered more than 100,000 vehicles in China to date. The company boasts a fleet of five emission-free, fully battery-powered models, ranging from sports cars to luxury sedans and full-size SUVs. In addition to their vehicles, NIO is also known for their significant progress achieved in innovative technology, including state-of-the-art battery solutions, artificial intelligence, and autonomous driving. The company has also recently turned their global expansion plans into reality, with the first overseas NIO store to open in Oslo, Norway in Q3 2021. We believe that reaching a share price of $100 is no longer a question of “if”, but instead, “when”.</p>\n<p><b>A Trailblazer in Innovative Technology</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/16d9fd877602d5604bc3a69593badfdf\" tg-width=\"640\" tg-height=\"262\"><span>Source:ir.nio.com</span></p>\n<p>NIO has continuously exhibited characteristics of an unsettling innovator. The brand is widely known for their breakthrough in battery swapping technology, “Power Swap”, which provides NIO owners with a fast and convenient solution to concerns over the typically limited travel range of EVs. Similar to a gas station, Power Swap is a battery swapping station that can swap a dead battery out for a fully charged one in under three minutes; a fully charged battery enables a NIO vehicle to travel up to 435 miles, which is more than double of the&nbsp;181-mile average travel range of electric vehicles&nbsp;currently available on the market. NIO owners have the option to subscribe to the“Battery as a Service” (“BaaS”)package, which is a monthly subscription service that provides NIO owners with flexible options for battery upgrades based on personal needs. The company currently offers a standard 75 kWh battery which enables a travel range of up to 310 miles on a full charge, and an enhanced 100 kWh battery which enables a travel range of up to 435 miles on a full charge; both are available for NIO owners to choose from on a month-to-month basis under BaaS. To date, there are&nbsp;more than 226 battery swapping stations&nbsp;across China, with more on the way following a recent&nbsp;strategic partnership agreement&nbsp;between NIO and Sinopec. NIO’s vehicles are also compatible with local competitor XPeng’s(NYSE:XPEV)1,140 vehicle charging stations available across 164 cities in China, which further enhances its existing network of charging infrastructure in place for NIO owners.</p>\n<p>In addition to the developed network of infrastructure needed to sustain NIO EVs in the long run, the company has also been working diligently on perfecting their autonomous driving and AI technology in order to remain competitive in the broader EV and tech space. NIO has already been performing testing on its autonomous driving systems since 2016, with their first testing on public roads in Beijing performed in 2018. The company’s commitment to the future of passenger transportation is also proven through their development of&nbsp;EVE, the brand’s concept car for autonomous driving which encompasses a luxurious, comfortable and safe experience powered by NIO’s&nbsp;NOMI AI, the world’s first in-vehicle artificial intelligence.</p>\n<p>To further enhance their progress in autonomous driving technology, NIO has recently&nbsp;partnered with Mobileye&nbsp;– an Intel-owned(NASDAQ:INTC)company known for developing the “EyeQ chip” currently used by more than 27 car manufacturers for their assisted-driving technologies – to develop and commercialize driving automation that does not require human interaction (i.e. “level 4” autonomous driving). Their collaboration is expected to accelerate NIO’s launch of the “Autonomous Driving as a Service” (“ADaaS”) package, which is a monthly subscription for their autonomous driving technology, “NIO Autonomous Driving” (“NAD”). However, similar to Tesla’s “Full Self-Driving” package, the NAD technology that is expected to launch in 2022 does not yet make NIO vehicles capable of driving without human intervention, but it does catapult NIO to a comparable spot with industry leader Tesla in the race towards level 4 autonomous driving. NIO owners will have the option to subscribe to ADaaS for a monthly subscription fee of RMB 680. With more than 102,000 NIO vehicles on the road today, the new subscription package is expected to generate incremental annual sales of RMB 840 million ($132 million); the additional revenue stream is valued at approximately RMB 10 billion ($1.6 billion) upon the service’s inception, assuming an average vehicle life of 12 years with most existing NIO owners signing up.</p>\n<p>NIO’s continuous developments in autonomous driving technology are expected to benefit the company and its shareholders greatly in the near future. By 2025, the global autonomous cars market will become one of the fastest growing and most highly demanded segments with an&nbsp;estimated value of $1.6 trillion. A 6% share of this market would add a valuation of at least $100 billion to NIO’s existing $67 billion market cap, boosting its per unit share value to more than $100. Considering NIO is currently one of the very few fully electric automakers to have achieved tangible results within the autonomous driving scene, and is actively growing its overseas sales, we are confident that the company is capable of capturing more than 6% of the said market share, and achieve a per unit share price of more than $100 by 2025 with ease. Combined with the global shift in consumer preference towards electrification and automation, we are projecting vehicle sales of approximately 300,000 units by FY 2025, which will yield total revenues of approximately RMB 140 billion ($22 billion).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6c800a04e6df92802f6893d214eecdd\" tg-width=\"640\" tg-height=\"213\"><span>Source: Author, with data from our internal forecasts (NIO_-_Forecasted_Financial_Information.pdf).</span></p>\n<p><b>Global Expansion</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537449f8f7ee9c736b48c1776cbb7259\" tg-width=\"640\" tg-height=\"249\"><span>Source: ir.nio.com</span></p>\n<p>Another catalyst that will propel NIO’s share price beyond $100 is their ongoing overseas expansion efforts. NIO has been transparent about their intentions to expand globally, especially in the U.S. and Europe, as part of their plans in becoming an industry leader. NIO will be opening its first&nbsp;overseas sales and service centre in Oslo, Norway&nbsp;in September. The brand’s footprint in Norway will further expand in 2022 with four more NIO stores to open in Bergen, Stavanger, Trondheim and Kristiansand. In addition to its direct sales and service centres, NIO will also be introducing a full charging map for Europe, starting with four NIO Power Swap stations in Norway to provide new NIO owners with the convenience and range that the brand builds its success on. NIO’s flagship SUV, the&nbsp;ES8, which currently retails at a&nbsp;starting price of approximately US$67,000, will be the first model introduced in the European market, with the brand’s newest full-size sedan, the&nbsp;ET7, to follow in 2022.</p>\n<p>With a proven sales track record in China’s luxury EV market, and specs comparable to the globally recognized Tesla, there is no reason for NIO to not succeed overseas. As mentioned in earlier sections, NIO’s vehicles have a driving range of up to 435 miles on a full charge, making it a desirable choice for potential European and American car owners looking for a reliable companion to accompany them on daily commutes to long road trips. The NIO exterior and interior designs are also modern, luxurious, and comparable to those preferred by the European and North American population. Combined with a diverse product line and price range, NIO is equipped to take on the increasing demands for EVs on a global scale.</p>\n<p><b>NIO’s Historical Performance</b></p>\n<p>Just a little more than a year ago, NIO’s share price hit an all-time low at under $2 amidst liquidity troubles despite continued vehicle sales. In mid-2020, the municipal government of Hefei, China came to NIO’s rescue with a&nbsp;capital injection of RMB 7 billion&nbsp;(approximately $1 billion). The arrangement resulted in the creation of “NIO China”, which serves as the operating entity that holds all of NIO’s core businesses and assets; NIO currently holds a 90.36% ownership interest in NIO China, while the “Hefei Strategic Investors” consortium holds the remainder 9.64%. The partnership became the company’s lifeline; the additional capital brought forth significant improvements to the company’s operations and vehicle sales, which were reflected in their strong financial performance and upward trend in share price in the summer of 2020. By the end of 2020’s second quarter, NIO’s share price rebounded by almost 20% on average after posting a 171% quarter-over-quarter increase in total revenues. The company’s share price more than tripled in 2020’s third quarter, averaging $15.40, and continued to climb towards its fourth quarter average of $38.70. By the end of the latest quarter ended March 31st, 2021, NIO’s share price averaged $50.97, and peaked at almost $62 in February which is more than 10x its&nbsp;IPO price in 2018. The company holds a market cap of more than $67 billion today, outgrowing its mere $1 billion market cap when it made its debut on the NYSE.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75a1d7edb18c1762028ba54f617e1982\" tg-width=\"640\" tg-height=\"250\"><span>Source: Author, with data from ir.nio.com</span></p>\n<p>NIO’s fundamentals have also shown nothing but steady improvements since its share price peaked earlier this year before the&nbsp;growth stock sell-off in late February. Deliveries in 2021 have continued to accelerate exponentially, with first quarter deliveries of more than 20,000 vehicles, representing almost 50% of total deliveries made in 2020. The company continues to exhibit a promising outlook with more than 7,100 vehicles delivered in April, representing an increase of more than 125% year-over-year. NIO has also maintained positive cash flows from operating activities for the first quarter of 2021, thanks to the higher deliveries and effective cost-management measures which have amped up their gross profit margin to 19.5%, comparable with industry leaders like Tesla whose first quarter gross margins were 21%. As aforementioned, we are forecasting vehicle sales of close to 300,000 units by FY 2025, which translates to approximately RMB 140 billion ($22 billion) in total revenues ($18.60 per share). Our vehicle sales forecast for FY 2025 is further corroborated by the&nbsp;recently renewed manufacturing agreement&nbsp;with joint venturer “Jianghuai Automobile Group” (“JAC”), which increases the current annual production capacity of 100,000 units to 240,000 units; the ongoing construction of “NeoPark” in Hefei, China is also expected to add annual production capacity of 1 million units, which further supports our positive outlook on NIO’s continued commitment to grow its business. Considering industry peer Tesla’s current P/S ratio of 16.43x with approximately $42 billion in annual revenues (annualization of $10.389 billion in first quarter revenues), the same proportion applied to NIO’s forecasted FY 2025 total revenues is expected to yield a P/S ratio of 8.7x, resulting in a share price of more than $160.</p>\n<p><b>NIO vs. LI and XPEV</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/af8fa939f92be448d1f427a6ac4bfb25\" tg-width=\"640\" tg-height=\"352\"><span>Source: Finviz</span></p>\n<p>We have also compared NIO’s current P/S ratio to its domestic peers to gauge the timeline in which NIO’s share price will exceed $100. NIO currently trades at a P/S ratio of approximately 14.88x, while domestic industry peers, Li Auto(NASDAQ:LI)and XPEV, currently trade at a P/S ratio of 14.46x and 21.31x, respectively.</p>\n<p>Considering NIO’s technology, revenues, global footprint, and cash flows are stronger than LI’s and XPEV’s, the former deserves to be traded at a much higher multiple than the latter two. Even if NIO reaches a P/S ratio of 18.1x (mid-point to XPEV's), it will drive the company’s current share price up to $51.50, which represents an upside potential of 22% based on the last traded share price of $42.34 (June 1st). And based on our forecasted revenues for FY 2025 for NIO of RMB 140 billion ($22 billion), or $18.60 per share, even a multiple half of the 18.1x would be more than sufficient to bring NIO's share price beyond $160 by 2025; we believe the trading multiple is achievable for NIO given the cash from operations and technological advancements achieved by then would place them on a trajectory of continued long-term growth within the EV industry, which is expected to continue into 2030 and beyond when the brand's level 4 autonomous driving technology development is complete and commercialized.</p>\n<p><b>Business Risks and Challenges</b></p>\n<p>As mentioned in one of my&nbsp;previous articles on NIO, the “Holding Foreign Companies Accountable Act” (“HFCA Act”) remains one of the most significant impending threats to the company’s share price. Currently, public accounting firms in China are non-compliant with PCAOB inspection rules required by the SEC, and the enactment of the HFCA Act in December 2020 requires that these public accounting firms comply with PCAOB inspection requests within three years of the enactment date; otherwise, all public companies audited by said firms will be subject to risks of de-listing. NIO is currently audited by PricewaterhouseCoopers Zhong Tian LLP, which is on PCAOB’s&nbsp;denied-access list. The potential threat of being delisted from the NYSE could be a deterrence factor to investors and ultimately hemorrhage NIO’s share price in the long run if Chinese authorities and the PCAOB cannot reach an agreement on conducting inspections soon.</p>\n<p>Another imminent challenge to NIO’s business is the ongoing global chip supply shortage. As the automotive industry becomes more dependent on chips to manage every function of their vehicles, the gap between automaker demands and chip manufacturer supplies is widened. NIO was no exception to the impacts of the ongoing chip supply crisis – in March 2021, NIO halted their production activity at the JAC-NIO manufacturing plant for five working days in order to adjust their production levels. However, the company continues to effectively navigate through the situation as proven through their increasing number of deliveries month-over-month; in NIO’s latest delivery update press release for April, the company has continued to keep up with market demand with more than 7,100 vehicle deliveries made, representing a 125% year-over-year growth.</p>\n<p>Competition within the EV sector has also ramped up in recent years. Consumer attitude towards EVs has changed drastically in the past decade due to rising concerns over climate change met with price parity between traditional petrol-fueled vehicles and EVs. The entry barrier for emerging EV makers has also lowered significantly as car battery solutions become more accessible through third-party OEMs; new entrants are now keener on participating in the profitable opportunity within the growing EV sector as initial investments become more reasonable than it was for Tesla in 2003 when EVs were still just a concept to many. In addition to new entrants, traditional petrol-fueled automakers like Ford(NYSE:F)have also started to incorporate fully battery-powered vehicles into their fleet in order to meet evolving consumer demands and remain competitive within the automotive industry. However, we believe NIO possesses the brand, customer experience, production strategy, talent and business model (further analyzedhere) needed to remain successful within the new competitive landscape in the long run.</p>\n<p><b>Conclusion</b></p>\n<p>NIO has already established a strong brand presence within the domestic Chinese market, which is currently one of the fastest growing EV markets, representing more than 40% of global EV sales in 2020. Combined with their proven ability to produce quality EVs, construct innovative charging infrastructure, achieve breakthrough progress in the development of autonomous driving technology, and execute their overseas expansion strategy, NIO is effectively narrowing the gap between them and Tesla within the EV sector on a global scale. We are confident that the next five years will be a transformational era for the EV and tech company due to increasing demands for electrification and automation within the automotive industry, which NIO has already proven to excel in. The value of its continued achievements will be reflected in its share price in no time, making them a worthy stock pick for those looking to profit off of the impending age of green transition and automation.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can NIO Stock Reach $100? We Think It's A Matter Of 'When' Not 'If'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan NIO Stock Reach $100? We Think It's A Matter Of 'When' Not 'If'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-05 12:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4432901-nio-stock-reach-100><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nNIO's share price has soared by more than 816% in the past year, peaking at almost $62 in early February before the growth stock sell-off in early March.\nThe company's innovative approach and...</p>\n\n<a href=\"https://seekingalpha.com/article/4432901-nio-stock-reach-100\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/article/4432901-nio-stock-reach-100","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148130971","content_text":"Summary\n\nNIO's share price has soared by more than 816% in the past year, peaking at almost $62 in early February before the growth stock sell-off in early March.\nThe company's innovative approach and overseas expansion strategy, combined with the growing market sentiment on global electrification and automation are expected to boost the company's valuation.\nWe believe NIO's share price will soar beyond $160 by 2025 as global EV sales continue to ramp up with autonomous driving becoming a reality.\n\nPhoto by Drew Angerer/Getty Images News via Getty Images\nDespite it being a local Chinese electric vehicle (“EV”) brand that has only recently started its overseas expansion into Europe, NIO(NYSE:NIO)has already garnered significant international attention amidst avid investors within the EV sector in recent years. It has only been three short years since NIO made its first deliveries in mid-2018, yet many are already wondering whether its share price can reach similar heights as an industry leader, Tesla’s(NASDAQ:TSLA). Albeit a little farfetched given Tesla is currently trading at more than $600 per share with a market cap of more than $600 billion, we do believe NIO has promising potential to break $100 per share before 2025. Even Wall Street Analysts remain optimistic about the company’s future by assigning a price target of close to $60, which represents upward potential of more than 35% based on the last traded share price of $42.34 (June 1st).\nFounded in 2014, NIO has sold and delivered more than 100,000 vehicles in China to date. The company boasts a fleet of five emission-free, fully battery-powered models, ranging from sports cars to luxury sedans and full-size SUVs. In addition to their vehicles, NIO is also known for their significant progress achieved in innovative technology, including state-of-the-art battery solutions, artificial intelligence, and autonomous driving. The company has also recently turned their global expansion plans into reality, with the first overseas NIO store to open in Oslo, Norway in Q3 2021. We believe that reaching a share price of $100 is no longer a question of “if”, but instead, “when”.\nA Trailblazer in Innovative Technology\nSource:ir.nio.com\nNIO has continuously exhibited characteristics of an unsettling innovator. The brand is widely known for their breakthrough in battery swapping technology, “Power Swap”, which provides NIO owners with a fast and convenient solution to concerns over the typically limited travel range of EVs. Similar to a gas station, Power Swap is a battery swapping station that can swap a dead battery out for a fully charged one in under three minutes; a fully charged battery enables a NIO vehicle to travel up to 435 miles, which is more than double of the 181-mile average travel range of electric vehicles currently available on the market. NIO owners have the option to subscribe to the“Battery as a Service” (“BaaS”)package, which is a monthly subscription service that provides NIO owners with flexible options for battery upgrades based on personal needs. The company currently offers a standard 75 kWh battery which enables a travel range of up to 310 miles on a full charge, and an enhanced 100 kWh battery which enables a travel range of up to 435 miles on a full charge; both are available for NIO owners to choose from on a month-to-month basis under BaaS. To date, there are more than 226 battery swapping stations across China, with more on the way following a recent strategic partnership agreement between NIO and Sinopec. NIO’s vehicles are also compatible with local competitor XPeng’s(NYSE:XPEV)1,140 vehicle charging stations available across 164 cities in China, which further enhances its existing network of charging infrastructure in place for NIO owners.\nIn addition to the developed network of infrastructure needed to sustain NIO EVs in the long run, the company has also been working diligently on perfecting their autonomous driving and AI technology in order to remain competitive in the broader EV and tech space. NIO has already been performing testing on its autonomous driving systems since 2016, with their first testing on public roads in Beijing performed in 2018. The company’s commitment to the future of passenger transportation is also proven through their development of EVE, the brand’s concept car for autonomous driving which encompasses a luxurious, comfortable and safe experience powered by NIO’s NOMI AI, the world’s first in-vehicle artificial intelligence.\nTo further enhance their progress in autonomous driving technology, NIO has recently partnered with Mobileye – an Intel-owned(NASDAQ:INTC)company known for developing the “EyeQ chip” currently used by more than 27 car manufacturers for their assisted-driving technologies – to develop and commercialize driving automation that does not require human interaction (i.e. “level 4” autonomous driving). Their collaboration is expected to accelerate NIO’s launch of the “Autonomous Driving as a Service” (“ADaaS”) package, which is a monthly subscription for their autonomous driving technology, “NIO Autonomous Driving” (“NAD”). However, similar to Tesla’s “Full Self-Driving” package, the NAD technology that is expected to launch in 2022 does not yet make NIO vehicles capable of driving without human intervention, but it does catapult NIO to a comparable spot with industry leader Tesla in the race towards level 4 autonomous driving. NIO owners will have the option to subscribe to ADaaS for a monthly subscription fee of RMB 680. With more than 102,000 NIO vehicles on the road today, the new subscription package is expected to generate incremental annual sales of RMB 840 million ($132 million); the additional revenue stream is valued at approximately RMB 10 billion ($1.6 billion) upon the service’s inception, assuming an average vehicle life of 12 years with most existing NIO owners signing up.\nNIO’s continuous developments in autonomous driving technology are expected to benefit the company and its shareholders greatly in the near future. By 2025, the global autonomous cars market will become one of the fastest growing and most highly demanded segments with an estimated value of $1.6 trillion. A 6% share of this market would add a valuation of at least $100 billion to NIO’s existing $67 billion market cap, boosting its per unit share value to more than $100. Considering NIO is currently one of the very few fully electric automakers to have achieved tangible results within the autonomous driving scene, and is actively growing its overseas sales, we are confident that the company is capable of capturing more than 6% of the said market share, and achieve a per unit share price of more than $100 by 2025 with ease. Combined with the global shift in consumer preference towards electrification and automation, we are projecting vehicle sales of approximately 300,000 units by FY 2025, which will yield total revenues of approximately RMB 140 billion ($22 billion).\nSource: Author, with data from our internal forecasts (NIO_-_Forecasted_Financial_Information.pdf).\nGlobal Expansion\nSource: ir.nio.com\nAnother catalyst that will propel NIO’s share price beyond $100 is their ongoing overseas expansion efforts. NIO has been transparent about their intentions to expand globally, especially in the U.S. and Europe, as part of their plans in becoming an industry leader. NIO will be opening its first overseas sales and service centre in Oslo, Norway in September. The brand’s footprint in Norway will further expand in 2022 with four more NIO stores to open in Bergen, Stavanger, Trondheim and Kristiansand. In addition to its direct sales and service centres, NIO will also be introducing a full charging map for Europe, starting with four NIO Power Swap stations in Norway to provide new NIO owners with the convenience and range that the brand builds its success on. NIO’s flagship SUV, the ES8, which currently retails at a starting price of approximately US$67,000, will be the first model introduced in the European market, with the brand’s newest full-size sedan, the ET7, to follow in 2022.\nWith a proven sales track record in China’s luxury EV market, and specs comparable to the globally recognized Tesla, there is no reason for NIO to not succeed overseas. As mentioned in earlier sections, NIO’s vehicles have a driving range of up to 435 miles on a full charge, making it a desirable choice for potential European and American car owners looking for a reliable companion to accompany them on daily commutes to long road trips. The NIO exterior and interior designs are also modern, luxurious, and comparable to those preferred by the European and North American population. Combined with a diverse product line and price range, NIO is equipped to take on the increasing demands for EVs on a global scale.\nNIO’s Historical Performance\nJust a little more than a year ago, NIO’s share price hit an all-time low at under $2 amidst liquidity troubles despite continued vehicle sales. In mid-2020, the municipal government of Hefei, China came to NIO’s rescue with a capital injection of RMB 7 billion (approximately $1 billion). The arrangement resulted in the creation of “NIO China”, which serves as the operating entity that holds all of NIO’s core businesses and assets; NIO currently holds a 90.36% ownership interest in NIO China, while the “Hefei Strategic Investors” consortium holds the remainder 9.64%. The partnership became the company’s lifeline; the additional capital brought forth significant improvements to the company’s operations and vehicle sales, which were reflected in their strong financial performance and upward trend in share price in the summer of 2020. By the end of 2020’s second quarter, NIO’s share price rebounded by almost 20% on average after posting a 171% quarter-over-quarter increase in total revenues. The company’s share price more than tripled in 2020’s third quarter, averaging $15.40, and continued to climb towards its fourth quarter average of $38.70. By the end of the latest quarter ended March 31st, 2021, NIO’s share price averaged $50.97, and peaked at almost $62 in February which is more than 10x its IPO price in 2018. The company holds a market cap of more than $67 billion today, outgrowing its mere $1 billion market cap when it made its debut on the NYSE.\nSource: Author, with data from ir.nio.com\nNIO’s fundamentals have also shown nothing but steady improvements since its share price peaked earlier this year before the growth stock sell-off in late February. Deliveries in 2021 have continued to accelerate exponentially, with first quarter deliveries of more than 20,000 vehicles, representing almost 50% of total deliveries made in 2020. The company continues to exhibit a promising outlook with more than 7,100 vehicles delivered in April, representing an increase of more than 125% year-over-year. NIO has also maintained positive cash flows from operating activities for the first quarter of 2021, thanks to the higher deliveries and effective cost-management measures which have amped up their gross profit margin to 19.5%, comparable with industry leaders like Tesla whose first quarter gross margins were 21%. As aforementioned, we are forecasting vehicle sales of close to 300,000 units by FY 2025, which translates to approximately RMB 140 billion ($22 billion) in total revenues ($18.60 per share). Our vehicle sales forecast for FY 2025 is further corroborated by the recently renewed manufacturing agreement with joint venturer “Jianghuai Automobile Group” (“JAC”), which increases the current annual production capacity of 100,000 units to 240,000 units; the ongoing construction of “NeoPark” in Hefei, China is also expected to add annual production capacity of 1 million units, which further supports our positive outlook on NIO’s continued commitment to grow its business. Considering industry peer Tesla’s current P/S ratio of 16.43x with approximately $42 billion in annual revenues (annualization of $10.389 billion in first quarter revenues), the same proportion applied to NIO’s forecasted FY 2025 total revenues is expected to yield a P/S ratio of 8.7x, resulting in a share price of more than $160.\nNIO vs. LI and XPEV\nSource: Finviz\nWe have also compared NIO’s current P/S ratio to its domestic peers to gauge the timeline in which NIO’s share price will exceed $100. NIO currently trades at a P/S ratio of approximately 14.88x, while domestic industry peers, Li Auto(NASDAQ:LI)and XPEV, currently trade at a P/S ratio of 14.46x and 21.31x, respectively.\nConsidering NIO’s technology, revenues, global footprint, and cash flows are stronger than LI’s and XPEV’s, the former deserves to be traded at a much higher multiple than the latter two. Even if NIO reaches a P/S ratio of 18.1x (mid-point to XPEV's), it will drive the company’s current share price up to $51.50, which represents an upside potential of 22% based on the last traded share price of $42.34 (June 1st). And based on our forecasted revenues for FY 2025 for NIO of RMB 140 billion ($22 billion), or $18.60 per share, even a multiple half of the 18.1x would be more than sufficient to bring NIO's share price beyond $160 by 2025; we believe the trading multiple is achievable for NIO given the cash from operations and technological advancements achieved by then would place them on a trajectory of continued long-term growth within the EV industry, which is expected to continue into 2030 and beyond when the brand's level 4 autonomous driving technology development is complete and commercialized.\nBusiness Risks and Challenges\nAs mentioned in one of my previous articles on NIO, the “Holding Foreign Companies Accountable Act” (“HFCA Act”) remains one of the most significant impending threats to the company’s share price. Currently, public accounting firms in China are non-compliant with PCAOB inspection rules required by the SEC, and the enactment of the HFCA Act in December 2020 requires that these public accounting firms comply with PCAOB inspection requests within three years of the enactment date; otherwise, all public companies audited by said firms will be subject to risks of de-listing. NIO is currently audited by PricewaterhouseCoopers Zhong Tian LLP, which is on PCAOB’s denied-access list. The potential threat of being delisted from the NYSE could be a deterrence factor to investors and ultimately hemorrhage NIO’s share price in the long run if Chinese authorities and the PCAOB cannot reach an agreement on conducting inspections soon.\nAnother imminent challenge to NIO’s business is the ongoing global chip supply shortage. As the automotive industry becomes more dependent on chips to manage every function of their vehicles, the gap between automaker demands and chip manufacturer supplies is widened. NIO was no exception to the impacts of the ongoing chip supply crisis – in March 2021, NIO halted their production activity at the JAC-NIO manufacturing plant for five working days in order to adjust their production levels. However, the company continues to effectively navigate through the situation as proven through their increasing number of deliveries month-over-month; in NIO’s latest delivery update press release for April, the company has continued to keep up with market demand with more than 7,100 vehicle deliveries made, representing a 125% year-over-year growth.\nCompetition within the EV sector has also ramped up in recent years. Consumer attitude towards EVs has changed drastically in the past decade due to rising concerns over climate change met with price parity between traditional petrol-fueled vehicles and EVs. The entry barrier for emerging EV makers has also lowered significantly as car battery solutions become more accessible through third-party OEMs; new entrants are now keener on participating in the profitable opportunity within the growing EV sector as initial investments become more reasonable than it was for Tesla in 2003 when EVs were still just a concept to many. In addition to new entrants, traditional petrol-fueled automakers like Ford(NYSE:F)have also started to incorporate fully battery-powered vehicles into their fleet in order to meet evolving consumer demands and remain competitive within the automotive industry. However, we believe NIO possesses the brand, customer experience, production strategy, talent and business model (further analyzedhere) needed to remain successful within the new competitive landscape in the long run.\nConclusion\nNIO has already established a strong brand presence within the domestic Chinese market, which is currently one of the fastest growing EV markets, representing more than 40% of global EV sales in 2020. Combined with their proven ability to produce quality EVs, construct innovative charging infrastructure, achieve breakthrough progress in the development of autonomous driving technology, and execute their overseas expansion strategy, NIO is effectively narrowing the gap between them and Tesla within the EV sector on a global scale. We are confident that the next five years will be a transformational era for the EV and tech company due to increasing demands for electrification and automation within the automotive industry, which NIO has already proven to excel in. The value of its continued achievements will be reflected in its share price in no time, making them a worthy stock pick for those looking to profit off of the impending age of green transition and automation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184367130,"gmtCreate":1623685148320,"gmtModify":1704208733132,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"hibjjhjj","listText":"hibjjhjj","text":"hibjjhjj","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184367130","isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101708843,"gmtCreate":1619938443982,"gmtModify":1704336606575,"author":{"id":"3581745590028997","authorId":"3581745590028997","name":"Soris","avatar":"https://static.tigerbbs.com/94b9d5134a959d48058b5db1369ef4b5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581745590028997","authorIdStr":"3581745590028997"},"themes":[],"htmlText":"like me","listText":"like me","text":"like me","images":[{"img":"https://static.tigerbbs.com/2ea63e3418352fd346eb3cde1eaa52b1","width":"750","height":"1260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101708843","isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}